Follow
"In the last 20 years, numerous other HER2-targeted therapies have proven successful in the metastatic, adjuvant and neoadjuvant settings, including another monoclonal antibody — pertuzumab — three separate tyrosine kinase inhibitors — lapatinib, neratinib, and tucatinib — and two antibody drug conjugates (ADCs) — ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (TDx-D)."
